Education
About Us
Working with TipRanks
Follow Us
Electromed (ELMD)
XASE:ELMD
ELMD Stock Chart & Stats
$24.83
$0.65(2.15%)
At close: 4:00 PM EST
$24.83
$0.65(2.15%)
Day’s Range― - ―
52-Week Range$17.73 - $30.73
Previous CloseN/A
Volume34.94K
Average Volume (3M)83.15K
Market Cap
$198.44M
Enterprise Value$190.23M
Total Cash (Recent Filing)$13.79M
Total Debt (Recent Filing)$96.00K
Price to Earnings (P/E)21.8
Beta0.77
Next Earnings
May 12, 2026EPS Estimate
0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.32
Shares Outstanding8,275,313
10 Day Avg. Volume63,597
30 Day Avg. Volume83,149
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)4.24
Price to Sales (P/S)2.86
P/FCF Ratio16.53
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue2.76
Enterprise Value/Gross Profit3.53
Enterprise Value/Ebitda14.91
Forecast
1Y Price Target
$37.33Price Target Upside50.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)1.1
Revenue Forecast (FY)$71.98M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthElectromed’s near-zero leverage and meaningful liquidity create durable financial flexibility for multi-quarter investments or downturns. A strong equity base and cash buffer reduce refinancing risk, support buybacks or targeted growth spend, and preserve optionality for strategic initiatives.
High And Expanding MarginsSustained gross margins near the mid-70s plus rising net margin reflect durable unit economics and manufacturing optimization. High margin structure supports reinvestment in sales and education while providing operating leverage that can amplify returns as revenue grows.
Commercial / Payer ExpansionBroadening payer coverage and CRM/Smart Order adoption deepen distribution and reduce friction to patient access. Combined with salesforce productivity gains and completed manufacturing optimization, these structural go-to-market improvements underpin scalable, repeatable homecare revenue growth over coming quarters.
Bears Say
Revenue Growth DecelerationA notable slowdown in trailing growth versus prior multi-year expansion signals tougher upcoming comparisons or market saturation headwinds. If sustained, slower top-line momentum could limit operating leverage benefits and pressure near-term margin expansion expectations.
Historical Cash-flow VolatilityAlthough recent free cash flow improved, prior multi-year variability indicates cash generation is cyclical and subject to operational timing. This history raises the bar for forecasting durable free cash flow, requiring ongoing monitoring of working capital, capex, and the impact of commercial investments.
Under‑penetration & Channel ConcentrationA large education gap and reliance on homecare sales concentrate execution risk: sustained market penetration requires clinician education and payer engagement. Hospital channel softness and concentrated homecare exposure mean adoption obstacles or channel shifts could slow durable revenue growth.
Electromed News
ELMD FAQ
What was Electromed’s price range in the past 12 months?
Electromed lowest stock price was $17.73 and its highest was $30.73 in the past 12 months.
What is Electromed’s market cap?
Electromed’s market cap is $198.44M.
When is Electromed’s upcoming earnings report date?
Electromed’s upcoming earnings report date is May 12, 2026 which is in 67 days.
How were Electromed’s earnings last quarter?
Electromed released its earnings results on Feb 10, 2026. The company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.26 by $0.06.
Is Electromed overvalued?
According to Wall Street analysts Electromed’s price is currently Undervalued.
Does Electromed pay dividends?
Electromed does not currently pay dividends.
What is Electromed’s EPS estimate?
Electromed’s EPS estimate is 0.24.
How many shares outstanding does Electromed have?
Electromed has 8,275,313 shares outstanding.
What happened to Electromed’s price movement after its last earnings report?
Electromed reported an EPS of $0.32 in its last earnings report, beating expectations of $0.26. Following the earnings report the stock price went down -9.979%.
Which hedge fund is a major shareholder of Electromed?
Currently, no hedge funds are holding shares in ELMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Electromed Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$37.33 (50.34% Upside)
$37.33 (50.34% Upside)
Blogger Sentiment
Bullish
ELMD Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $1.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.6%
Last 30 Days ▲ 20.1%
Last 30 Days ▲ 20.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-6.75%
12-Months-Change
Fundamentals
Return on Equity
20.20%
Trailing 12-Months
Asset Growth
5.04%
Trailing 12-Months
Company Description
Electromed
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system; SmartVest SQL System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment; and SmartVest Connect, a wireless technology with personalized HFCWO therapy management portal for patients with compromised pulmonary function. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products primarily to home health care market for patients with bronchiectasis, cystic fibrosis, and neuromuscular disease. Electromed, Inc. markets its products primarily to physicians and health care providers, as well as directly to patients. The company was incorporated in 1992 and is headquartered in New Prague, Minnesota.
ELMD Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a strongly positive operational and financial picture: record revenue growth, meaningful margin expansion, robust home-care execution, and multiple strategic initiatives (payer contracts, digital order flow, CRM, manufacturing optimization). The main negatives are a decline in hospital and other revenues, a one-time-like cash reduction driven by share repurchases, higher SG&A tied to growth investments, and a meaningful market education gap (58% of qualifying patients not receiving therapy). Taken together, the positives (sustained top-line growth, improved profitability, balance sheet strength, and clear large addressable market) materially outweigh the near-term challenges and risks discussed.View all ELMD earnings summariesELMD Stock 12 Month Forecast
Average Price Target
$37.33
▲(50.34% Upside)
Technical Analysis
Ownership Overview
7.21% Insiders
10.31% Mutual Funds
15.73% Other Institutional Investors
57.35% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---